The Wilms tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression

Nature Communications

Volumn 5, Issue , 2014, Pages

  Wagner, Kay Dietrich ^a   Cherfils Vicini, Julien ^a   Hosen, Naoki ^b   Hohenstein, Peter ^c   Gilson, Eric ^a,d   Hastie, Nicholas D ^e   Michiels, Jean François ^a,d   Wagner, Nicole ^a  

^a UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^b OSAKA UNIVERSITY   (Japan)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; STEM CELL FACTOR RECEPTOR; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN; WT1 PROTEIN; SMALL INTERFERING RNA;

DISEASE INCIDENCE; GENE EXPRESSION; GERM CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; SURVIVORSHIP; TUMOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; GENE INACTIVATION; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNOHISTOLOGY; MELANOMA CELL LINE; METASTASIS; MOUSE; NEPHROBLASTOMA; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; SURVIVAL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR REGRESSION; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CANCER TRANSPLANTATION; DISEASE COURSE; ENDOTHELIUM CELL; EXPERIMENTAL MELANOMA; FEMALE; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; TRANSGENIC MOUSE; TUMOR CELL CULTURE; TUMOR VOLUME; VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY, INNATE; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-KIT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR CELLS, CULTURED; WT1 PROTEINS;

EID: 84922621741     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6852     Document Type: Article

References (67)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Folkman, J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285, 1182-1186 (1971).
3. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
4. Casanovas, O., Hicklin, D. J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
5. Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
6. De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005).
7. Mazzieri, R. et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19, 512-526 (2011).
8. DeNardo, D. G. et al. CD4(\+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91-102 (2009).
9. Wagner, N., Michiels, J. F., Schedl, A. & Wagner, K. D. The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo. Oncogene 27, 3662-3672 (2008).
10. Haber, D. A. et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 61, 1257-1269 (1990).
11. Hohenstein, P. & Hastie, N. D. The many facets of the Wilms' tumour gene, WT1. Hum. Mol. Genet. 15, R196-R201 (2006).
12. Oka, Y., Tsuboi, A., Oji, Y., Kawase, I. & Sugiyama, H. WT1 peptide vaccine for the treatment of cancer. Curr. Opin. Immunol. 20, 211-220 (2008).
13. Kreidberg, J. A. et al. WT-1 is required for early kidney development. Cell 74, 679-691 (1993).
14. Goldstein, N. S. & Uzieblo, A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am. J. Clin. Pathol. 117, 541-545 (2002).
15. Wagner, N., Panelos, J., Massi, D. & Wagner, K. D. The Wilms' tumor suppressor WT1 is associated with melanoma proliferation. Pflugers Arch. 455, 839-847 (2008).
16. Hosen, N. et al. The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. Leukemia 21, 1783-1791 (2007).
17. Martnez-Estrada, O. M. et al. Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. Nat. Genet. 42, 89-93 (2010).
18. Forde, A., Constien, R., Grone, H. J., Hammerling, G. & Arnold, B. Temporal Cre-mediated recombination exclusively in endothelial cells using Tie2 regulatory elements. Genesis 33, 191-197 (2002).
19. Monvoisin, A. et al. VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. Dev. Dyn. 235, 3413-3422 (2006).
20. Coffelt, S. B. et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J. Immunol. 186, 4183-4190 (2011).
21. Liu-Jarin, X. et al. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod. Pathol. 16, 1102-1108 (2003).
22. Ogston, K. N. et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12, 320-327 (2003).
23. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global doublefluorescent Cre reporter mouse. Genesis 45, 593-605 (2007).
24. Ziegler, S. F., Ramsdell, F. & Alderson, M. R. The activation antigen CD69. Stem Cells 12, 456-465 (1994).
25. Alter, G., Malenfant, J. M. & Altfeld, M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294, 15-22 (2004).
26. Aktas, E., Kucuksezer, U. C., Bilgic, S., Erten, G. & Deniz, G. Relationship between CD107a expression and cytotoxic activity. Cell. Immunol. 254, 149-154 (2009).
27. Drabkin, D. L. & Austin, J. H. Spectrophotometric studies: II. preparations from washed blood cells; nitric oxide hemoglobin and sulfhemoglobin. J. Biol. Chem. 112, 51-65 (1935).
28. Wagner, N. et al. Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms' tumor transcription factor Wt1. Genes Dev. 19, 2631-2642 (2005).
29. Wagner, K. D. et al. The Wilms' tumor suppressor Wt1 is expressed in the coronary vasculature after myocardial infarction. FASEB J. 16, 1117-1119 (2002).
30. Fidler, I. J. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35, 218-224 (1975).
31. Yoo, M. H., Xu, X. M., Carlson, B. A., Gladyshev, V. N. & Hatfield, D. L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem. 281, 13005-13008 (2006).
32. Dejong, V. et al. The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun. Oncogene 18, 3143-3151 (1999).
33. McCarty, G., Awad, O. & Loeb, D. M. WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. J. Biol. Chem. 286, 43634-43643 (2011).
34. Larsson, S. H. et al. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 81, 391-401 (1995).
35. Davies, R. C. et al. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev. 12, 3217-3225 (1998).
36. Broudy, V. C. et al. Human umbilical vein endothelial cells display high-affinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood 83, 2145-2152 (1994).
37. Sihto, H., Tynninen, O., Butzow, R., Saarialho-Kere, U. & Joensuu, H. Endothelial cell KIT expression in human tumours. J. Pathol. 211, 481-488 (2007).
38. Fang, S., Wei, J., Pentinmikko, N., Leinonen, H. & Salven, P. Generation of functional blood vessels from a single c-kit\+ adult vascular endothelial stem cell. PLoS Biol. 10, e1001407 (2012).
39. Zhou, B. et al. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 454, 109-113 (2008).
40. Inai, T. et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165, 35-52 (2004).
41. Levy, A. P., Levy, N. S., Wegner, S. & Goldberg, M. A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 270, 13333-13340 (1995).
42. Wagner, K. D. et al. Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). FASEB J. 17, 1364-1366 (2003).
43. Elvert, G. et al. Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J. Biol. Chem. 278, 7520-7530 (2003).
44. Dimaio, T. A. et al. Attenuation of retinal vascular development and neovascularization in PECAM-1-deficient mice. Dev. Biol. 315, 72-88 (2008).
45. DeLisser, H. M. et al. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am. J. Pathol. 151, 671-677 (1997).
46. Matsui, J., Wakabayashi, T., Asada, M., Yoshimatsu, K. & Okada, M. Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J. Biol. Chem. 279, 18600-18607 (2004).
47. Nolan, D. J. et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 21, 1546-1558 (2007).
48. Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
49. Srivastava, M. K. et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS ONE 7, e40677 (2012).
50. Katuri, V. et al. WT1 regulates angiogenesis in Ewing Sarcoma. Oncotarget 5, 2436-2449 (2014).
51. Talmadge, J. E. & Gabrilovich, D. I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13, 739-752 (2013).
52. El Mai, M. et al. The telomeric protein TRF2 regulates angiogenesis by binding and activating the PDGFRb promoter. Cell Rep. 9, 1047-1060 (2014).
53. Biroccio, A. et al. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat. Cell Biol. 15, 818-828 (2013).
54. Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717 (2005).
55. Lewis Phillips, G. D. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-9290 (2008).
56. Wagner, K. D. et al. An inducible mouse model for PAX2-dependent glomerular disease: insights into a complex pathogenesis. Curr. Biol. 16, 793-800 (2006).
57. Chau, Y. Y. et al. Acute multiple organ failure in adult mice deleted for the developmental regulator Wt1. PLoS Genet. 7, e1002404 (2011).
58. Chipman, R. K. & Fox, K. A. Oestrous synchronization and pregnancy blocking in wild house mice (Mus musculus). J. Reprod. Fertil. 12, 233-236 (1966).
59. Euhus, D. M., Hudd, C., LaRegina, M. C. & Johnson, F. E. Tumor measurement in the nude mouse. J. Surg. Oncol. 31, 229-234 (1986).
60. Tiscornia, G., Singer, O. & Verma, I. M. Production and purification of lentiviral vectors. Nat. Protoc. 1, 241-245 (2006).
61. Liang, C. C., Park, A. Y. & Guan, J. L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2, 329-333 (2007).
62. Staton, C. A., Reed, M. W. & Brown, N. J. A critical analysis of current in vitro and in vivo angiogenesis assays. Int. J. Exp. Pathol. 90, 195-221 (2009).
63. Collan, Y. & Romppannen, T. Morphometry in Morphological Diagnosis 40 (Kuopio Univ. Press, 1982).
64. Bolte, S. & Cordelières, F. P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213-232 (2006).
65. Messeguer, X. et al. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 18, 333-334 (2002).
66. Maeda, K., Nishiyama, C., Ogawa, H. & Okumura, K. GATA2 and Sp1 positively regulate the c-kit promoter in mast cells. J. Immunol. 185, 4252-4260 (2010).
67. Wagner, K. D., Benchetrit, M., Bianchini, L., Michiels, J. F. & Wagner, N. Peroxisome proliferator-activated receptor b/d (PPARb/d) is highly expressed in liposarcoma and promotes migration and proliferation. J. Pathol. 224, 575-588 (2011).